X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
TTP488 (azeliragon), is an orally active, small molecule, antagonist of the receptor for advanced glycation endproducts (RAGE). It is being investigated for the treatment of hospitalized patients for COVID-19 infection.
Lead Product(s): Azeliragon
Therapeutic Area: Infections and Infectious Diseases Product Name: TTP488
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Michigan Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 27, 2023
Details:
TTP488 (azeliragon), is an orally active, small molecule, antagonist of the receptor for advanced glycation endproducts (RAGE). It is being investigated for the treatment of refractory to first-line treatment of metastatic pancreatic cancer.
Lead Product(s): Azeliragon,Dexamethasone
Therapeutic Area: Oncology Product Name: TTP488
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 26, 2023
Details:
TTP488 (azeliragon), is an orally active, small molecule, antagonist of the receptor for advanced glycation endproducts (RAGE). It is being investigated for the treatment of patients newly diagnosed unmethylated glioblastoma.
Lead Product(s): Azeliragon
Therapeutic Area: Oncology Product Name: TTP488
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Lenox Hill Hospital
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 18, 2023
Details:
Azeliragon is an orally administered capsule, taken once daily, that inhibits interactions of RAGE with certain ligands, including HMGB1 and S100 proteins in the tumor microenvironment.
Lead Product(s): Azeliragon,Dexamethasone
Therapeutic Area: Oncology Product Name: TTP488
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 28, 2023
Details:
Under the agreement, Cantex gets exclusive worldwide license for intellectual property related to the potential use of TTP488 (azeliragon), a small molecule RAGE inhibitor, to treat, prevent or alleviate cancer treatment-related cognitive decline.
Lead Product(s): Azeliragon,Doxorubicin Hydrochloride,Cyclophosphamide
Therapeutic Area: Neurology Product Name: TTP488
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cantex Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 16, 2023
Details:
Under the agreement, Cantex obtained an exclusive worldwide license for intellectual property related to the potential use of TTP-488 (azeliragon) to treat, prevent or alleviate cancer-treatment related cognitive decline.
Lead Product(s): Azeliragon
Therapeutic Area: Psychiatry/Psychology Product Name: TTP-488
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cantex Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 01, 2023
Details:
TTP488 (azeliragon) is an orally administered small molecule, taken once daily, that inhibits interactions of the receptor for advanced glycation end products (known as RAGE) with certain ligands, including HMGB1 and S100 proteins in the glioblastoma microenvironment.
Lead Product(s): Azeliragon
Therapeutic Area: Oncology Product Name: TTP488
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2023
Details:
TTP488 (azeliragon) is an orally active, small molecule, antagonist of the receptor for advanced glycation endproducts (RAGE). By preventing interaction of RAGE with these ligands, azeliragon may inhibit glioblastoma and overcome its resistance to effective treatment.
Lead Product(s): Azeliragon
Therapeutic Area: Oncology Product Name: TTP488
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 16, 2023
Details:
TTP488 (azeliragon), is an orally active, small molecule, antagonist of the receptor for advanced glycation endproducts (RAGE). It is being investigated for the treatment of patients hospitalized for COVID-19.
Lead Product(s): Azeliragon
Therapeutic Area: Infections and Infectious Diseases Product Name: TTP488
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Michigan Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2023
Details:
TTP488 (azeliragon), is an orally active, small molecule, antagonist of the receptor for advanced glycation endproducts (RAGE). A broad range of evidence suggests that RAGE ligand interactions play a critical role in cancer and in inflammatory diseases.
Lead Product(s): Azeliragon
Therapeutic Area: Oncology Product Name: TTP488
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Miami Cancer Institute
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2023
Details:
TTP488 (Azeliragon), is an orally active, small molecule, antagonist of the receptor for advanced glycation endproducts (RAGE). A broad range of evidence suggests that RAGE ligand interactions play a critical role in cancer and in inflammatory diseases.
Lead Product(s): Azeliragon,Temozolomide
Therapeutic Area: Oncology Product Name: TTP488
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2023
Details:
Cantex also plans to initiate Phase 2 clinical trials exploring the therapeutic effect of azeliragon in pancreatic and breast cancers, where RAGE has been implicated in disease progression as well as in complications of treatment.
Lead Product(s): Azeliragon
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: TTP488
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Harvard University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 23, 2022
Details:
Azeliragon, also known as TTP488, is an orally active, small molecule, antagonist of the receptor for advanced glycation endproducts (RAGE). Cantex has obtained exclusive worldwide rights to develop and commercialize azeliragon, vTv’s novel antagonist of RAGE.
Lead Product(s): Azeliragon
Therapeutic Area: Oncology Product Name: TTP488
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Cantex Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 22, 2021
Details:
vTv intends to use the net proceeds from the transaction for general corporate purposes and to support mechanistic study of TTP399 in type 1 diabetes, and conducting a multiple-ascending dose study of HPP737 as an oral therapy for psoriasis.
Lead Product(s): Azeliragon
Therapeutic Area: Neurology Product Name: TTP488
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Lincoln Park Capital Fund
Deal Size: $47.0 million Upfront Cash: Undisclosed
Deal Type: Agreement November 24, 2020
Details:
Data from this subgroup demonstrated nominally significant differences favoring azeliragon compared with placebo on the ADAS-cog11, an instrument used to evaluate cognition.
Lead Product(s): Azeliragon
Therapeutic Area: Neurology Product Name: TTP488
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
